A view from the Center


Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

While some barriers remain, value-based contracting for drugs has clearly moved past the talking phase

by Sonal Shah, Senior Manager, Deloitte Center for Health Solutions, Deloitte Services LP

It’s been four years since the Deloitte Center for Health Solutions collaborated with the Network for Excellence in Health Innovation (NEHI) to discuss the implications of value-based care on pharmaceutical innovation. Back then, the idea of value-based contracting (VBC) for drugs hadn’t moved much beyond exploring the concept. While there were a few examples here and there,

Read more

Catalysts for change: Meet the life sciences regulator of the future

by Kevin Brault, Federal Health Care Sector Leader, Deloitte & Touche LLP

As technology continues to drive the health sector further ahead, regulators—particularly in life sciences—might need to become more agile so they can foster innovation while continuing to ensure product effectiveness and consumer safety. Regulatory bodies have historically issued rules and required industries to abide by them. But the future of health is being largely dictated by software.

Read more

In the absence of drug rebates, new alternatives are likely to emerge

by Joseph M. Coppola, Managing Director, Life Sciences Commercial and Market Access Practice Leader, Deloitte Consulting LLP

The administration’s efforts to reduce prescription drug spending have put drug rebates in the spotlight. If rebates lose their safe-harbor status—as my colleague George Van Antwerp outlined in his recent blog—other models are likely to emerge to replace them. At least initially, any change to the rebate model is likely to be limited to Medicare Part D,

Read more

The future of drug rebates: Are they to be or not to be?

by George Van Antwerp, Managing Director, Deloitte Consulting LLP

Nearly half of all Americans (49 percent) have at least one prescription drug, and 12 percent of the population has five or more, according to 2017 data from the Centers for Drug Control and Prevention (CDC). In 2016, $329 billion was spent on prescription drugs—an increase of nearly 30 percent from 2010.1

With so much money at stake,

Read more

The good, the bad, and the ugly of opioids: For large employers, the epidemic can stretch far beyond medical claims

by George Van Antwerp, Managing Director, Deloitte Consulting LLP

First the good news. While we are in the midst of an opioid epidemic, large employers have seen prescription rates fall significantly since peaking in 2009. That year, 17.3 percent of covered employees or dependents had at least one opioid prescription. People who work for large employers are now using fewer prescription opioids.1 This is likely due to an increased focus—among health plans and clinicians—on limiting opioid prescriptions among patients who might be at risk for opioid dependence.

Read more

Five barriers that could keep biosimilar manufacturers from cracking the US market

by James Forsyth, Director, Deloitte MCS Limited, and Cameron McClearn, Principal, Deloitte Consulting LLP

The biosimilars market in the US has lagged well behind the European market for more than a decade.1 While a recent push from the White House could help expand the use of biosimilars in the US, manufacturers could still face some significant challenges there.

In April, the administration released its “blueprint” for lowering drug prices and reducing out-of-pocket costs for US consumers.

Read more